Skip to main content
Erschienen in: Journal of General Internal Medicine 12/2021

22.06.2021 | Narrative Review

Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings

Harm Reduction in Outpatient Addiction Treatment

verfasst von: Jessica L. Taylor, MD, Samantha Johnson, BA, Ricardo Cruz, MD MPH, Jessica R. Gray, MD, Davida Schiff, MD, MSc, Sarah M. Bagley, MD, MSc

Erschienen in: Journal of General Internal Medicine | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Opioid use disorder (OUD) is increasingly recognized as a chronic, relapsing brain disease whose treatment should be integrated into primary care settings alongside other chronic conditions. However, abstinence from all non-prescribed substance use continues to be prioritized as the only desired goal in many outpatient, primary care–based treatment programs. This presents a barrier to engagement for patients who continue to use substances and who may be at high risk for complications of ongoing substance use such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), superficial and deep tissue infections, and overdose. Harm reduction aims to reduce the negative consequences of substance use and offers an alternative to abstinence as a singular goal. Incorporating harm reduction principles into primary care treatment settings can support programs in engaging patients with ongoing substance use and facilitate the delivery of evidence-based screening and prevention services. The objective of this narrative review is to describe strategies for the integration of evidence-based harm reduction principles and interventions into outpatient, primary care–based OUD treatment settings. We will offer specific tools for providers and programs including strategies to support safer injection practices, assess the risks and benefits of continuing medications for opioid use disorder in the setting of ongoing substance use, promote a non-stigmatizing program culture, and address the needs of special populations with ongoing substance use including adolescents, parents, and families.
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
This vignette represents a composite of many patients seen in the authors’ clinical practices and not an individual patient story.
 
Literatur
7.
Zurück zum Zitat Alpren C, Dawson EL, John B, et al. Opioid Use Fueling HIV Transmission in an Urban Setting: An Outbreak of HIV Infection Among People Who Inject Drugs—Massachusetts, 2015–2018. Am J Public Health. Published online November 14, 2019:e1-e8. doi:https://doi.org/10.2105/AJPH.2019.305366 Alpren C, Dawson EL, John B, et al. Opioid Use Fueling HIV Transmission in an Urban Setting: An Outbreak of HIV Infection Among People Who Inject Drugs—Massachusetts, 2015–2018. Am J Public Health. Published online November 14, 2019:e1-e8. doi:https://​doi.​org/​10.​2105/​AJPH.​2019.​305366
34.
Zurück zum Zitat Peterborough Drug Strategy. Developing an Opioid Overdose REsponse Protocol: Information for Workplaces.; 2018. Peterborough Drug Strategy. Developing an Opioid Overdose REsponse Protocol: Information for Workplaces.; 2018.
54.
Zurück zum Zitat Muncie HL, Yasinian Y, Oge’ L. Outpatient management of alcohol withdrawal syndrome. Am Fam Physician. 2013;88(9):589-595.PubMed Muncie HL, Yasinian Y, Oge’ L. Outpatient management of alcohol withdrawal syndrome. Am Fam Physician. 2013;88(9):589-595.PubMed
66.
68.
Zurück zum Zitat Giftos, Jon. Returning from incarceration: reducing risks of reentry for justice-involved patietns with opioid use disorder. Presented at the: The New England Office Based Addiction Treatmetn Extension for Community Health Outcomes Tele-Education Series; March 20, 2019; Boston Medical Center, Boston, MA. Giftos, Jon. Returning from incarceration: reducing risks of reentry for justice-involved patietns with opioid use disorder. Presented at the: The New England Office Based Addiction Treatmetn Extension for Community Health Outcomes Tele-Education Series; March 20, 2019; Boston Medical Center, Boston, MA.
69.
Zurück zum Zitat Centers for Disease Control and Prevention. Integrated Prevention Services for HIV Infection, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis for Persons Who Use Drugs Illicitly: Summary Guidance from CDC and the U.S. Department of Health and Human Services. MMWR. Published online 2012. Accessed August 5, 2020. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6105a1.htm Centers for Disease Control and Prevention. Integrated Prevention Services for HIV Infection, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis for Persons Who Use Drugs Illicitly: Summary Guidance from CDC and the U.S. Department of Health and Human Services. MMWR. Published online 2012. Accessed August 5, 2020. https://​www.​cdc.​gov/​mmwr/​preview/​mmwrhtml/​rr6105a1.​htm
71.
Zurück zum Zitat Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR. 2015;64(RR-03):1-137. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR. 2015;64(RR-03):1-137.
72.
Zurück zum Zitat Visconti AJ, Sell J, Greenblatt AD. Primary Care for Persons Who Inject Drugs. Am Fam Physician. 2019;99(2):109-116.PubMed Visconti AJ, Sell J, Greenblatt AD. Primary Care for Persons Who Inject Drugs. Am Fam Physician. 2019;99(2):109-116.PubMed
80.
Zurück zum Zitat Schechter-Perkins EM, Dwyer KH, Amin A, et al. Loop Drainage Is Noninferior to Traditional Incision and Drainage of Cutaneous Abscesses in the Emergency Department. Acad Emerg Med. Published online May 14, 2020. doi:https://doi.org/10.1111/acem.13981 Schechter-Perkins EM, Dwyer KH, Amin A, et al. Loop Drainage Is Noninferior to Traditional Incision and Drainage of Cutaneous Abscesses in the Emergency Department. Acad Emerg Med. Published online May 14, 2020. doi:https://​doi.​org/​10.​1111/​acem.​13981
83.
Zurück zum Zitat Wejnert C, Hess KL, Hall HI, et al. Vital Signs:: Trends in HIV Diagnoses, Risk Behaviors, and Prevention Among Persons Who Inject Drugs — United States. Morbidity and Mortality Weekly Report. 2016;65(47):1336-1342. Wejnert C, Hess KL, Hall HI, et al. Vital Signs:: Trends in HIV Diagnoses, Risk Behaviors, and Prevention Among Persons Who Inject Drugs — United States. Morbidity and Mortality Weekly Report. 2016;65(47):1336-1342.
91.
Zurück zum Zitat Substance Abuse and Mental Health Services Administration. The Opioid Crisis and the Black/African American Population: An Urgent Issue. Office of Behavioarl Health Equity, Substance Abuse and Mental Health Services Administration; 2020. Substance Abuse and Mental Health Services Administration. The Opioid Crisis and the Black/African American Population: An Urgent Issue. Office of Behavioarl Health Equity, Substance Abuse and Mental Health Services Administration; 2020.
Metadaten
Titel
Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings
Harm Reduction in Outpatient Addiction Treatment
verfasst von
Jessica L. Taylor, MD
Samantha Johnson, BA
Ricardo Cruz, MD MPH
Jessica R. Gray, MD
Davida Schiff, MD, MSc
Sarah M. Bagley, MD, MSc
Publikationsdatum
22.06.2021
Verlag
Springer International Publishing
Erschienen in
Journal of General Internal Medicine / Ausgabe 12/2021
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-021-06904-4

Weitere Artikel der Ausgabe 12/2021

Journal of General Internal Medicine 12/2021 Zur Ausgabe

Healing Arts

Red Nail Polish

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.